Studies performed in the oocyte-pairing system (11) have shown that both Gly179Cys mutated hemi-channels, and a mixture of the wild-type and Cys179Gly protein, result in a loss of function of the Cx32 ion channel (lack of junctional conductance). Thus, in at least functional terms, Gly179Cys could be classified as a loss-of-function mutation, similar to nonsense or deleted variants of GJB1. However this observation seems in contrast with the mild phenotype for CMT1X disease, observed in our family, if compared with the severe phenotype (early-onset neuropathy associated to marked functional disabilities) Inhibitors,research,lifescience,medical usually described

in Navitoclax concentration patients harboring nonsense mutations of the GJB1 gene (4, 12). The relationship between the severity of the CMT1X disease and the cell effects of the different GJB1 gene mutations is still controversial (13). A preliminary genotype-phenotype correlation Inhibitors,research,lifescience,medical between the type of mutations (frameshifts, deletions and premature truncations) in the GJBJ gene Inhibitors,research,lifescience,medical and the severity of clinical course, showed that a more severe phenotype in CMT1X is caused by missense mutations (14). Hahn et al. (12) on the other hand, suggested that missense mutations

of the GJB1- located in the cytoplasmic loop and the second trans-membrane domain – segregate with a mild CMT1X phenotype, whereas mutations at all other locations of the connexin 32 result in a severe CMT1X phenotype with an early age at onset and severe disability. Liang et al. (15) did not Inhibitors,research,lifescience,medical confirm these data in an extended study on patients with CMT1X carrying the F235C missense mutation. In fact they described this mutation in a severely affected 14-year-old girl with high-degree of scoliosis and markedly reduced motor-nerve conduction Inhibitors,research,lifescience,medical velocities (18-20 m/sec), although functional studies showed that F235C mutation results in open hemi-channels affecting cell viability. The relationship

between the clinical severity of CMT1X and the intra-cellular retention of Cx32 mutants was also investigated for a set of GJB1 gene mutations. By this approach, it was possible to assume that Levetiracetam Cx32 mutants retained in transfected cells, resulted in a more severe phenotype than those reaching the cell surface (16). This hypothesis was not confirmed in the study of Shy et al. (13) who analyzed a large cohort of CMT1X-affected males harboring 28 different GJB1 gene mutations. They demonstrated that the degree of clinical disability in CMT1X-affected patients does not correlate with specific GJB1 gene mutations, nor with the type of mutation (deletion, frameshift or missense mutation). Furthermore a marked clinical variability was observed even in patients harboring the same mutation (13). Our results are in agreement with those reported in studies carried out on large groups of CMT1X patients.